GE HealthCare Technologies (GEHC) Stock Could Be 23% Undervalued After FDA AI Clearance

Simply Wall St.06-22

GE HealthCare Technologies (GEHC) has drawn investor attention after receiving FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software, a new AI tool designed to support radiation therapy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645545044?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-06-22 13:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645545044","market":"nz","top_or_hot":-1,"title":"GE HealthCare Technologies (GEHC) Stock Could Be 23% Undervalued After FDA AI Clearance","media":"Simply Wall St.","content":"<div>\n<p>GE HealthCare Technologies (GEHC) has drawn investor attention after receiving FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software, a new AI tool designed to support radiation therapy ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/news/ge-healthcare-technologies-gehc-stock-could-be-23-undervalue\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GE HealthCare Technologies (GEHC) Stock Could Be 23% Undervalued After FDA AI Clearance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGE HealthCare Technologies (GEHC) Stock Could Be 23% Undervalued After FDA AI Clearance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-22 13:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/news/ge-healthcare-technologies-gehc-stock-could-be-23-undervalue><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GE HealthCare Technologies (GEHC) has drawn investor attention after receiving FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software, a new AI tool designed to support radiation therapy ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/news/ge-healthcare-technologies-gehc-stock-could-be-23-undervalue\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820561818.USD","symbol_name":"安联收益及增长平衡基金Cl AM DIS","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/news/ge-healthcare-technologies-gehc-stock-could-be-23-undervalue","article_id":"2645545044","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gehc/ge-healthcare-technologies/news/ge-healthcare-technologies-gehc-stock-could-be-23-undervalue","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645545044","pubTimestamp":1782105319,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GE HealthCare Technologies (GEHC) has drawn investor attention after receiving FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software, a new AI tool designed to support radiation therapy planning in oncology.\nSee our latest analysis for GE HealthCare Technologies.\nDespite the FDA clearance and recent focus on AI enabled imaging and software, GE HealthCare Technologies’ share price is trading at $61.59, with the 30 day share price return down 4.11% and the 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0149725797.USD":"汇丰美国股市经济规模基金","BK4588":"碎股","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4187":"航天航空与国防","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4501":"段永平概念","AIPO":"Defiance AI and Power Infrastructure ETF","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","ARTY":"ISHARES FUTURE AI & TECH ETF","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","BK4566":"资本集团","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","AGIX":"通用人工智能 ETF-AGIX","GE":"GE航空航天","BK4206":"工业集团企业","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","BK4082":"医疗保健设备","LABU":"三倍做多标普生物-Direxion","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","GEHC":"GE HEALTHCARE TECHNOLOGIES INC"},"translate_title":"FDA人工智能批准后，GE HealthCare Technologies(GEHC)股票可能被低估23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GEHC":1.5,"ARTY":1.5,"AGIX":1.5,"LABU":1.5,"GE":1.5,"CHAT":1.5,"AIPO":1.5},"content_text":"GE HealthCare Technologies (GEHC) has drawn investor attention after receiving FDA 510(k) clearance for its MIM Contour ProtégéAI+ 2.0 software, a new AI tool designed to support radiation therapy planning in oncology. See our latest analysis for GE HealthCare Technologies. Despite the FDA clearance and recent focus on AI enabled imaging and software, GE HealthCare Technologies’ share price is trading at $61.59, with the 30 day share price return down 4.11% and the 1 year total shareholder return down 13.44%. This suggests recent momentum has been weaker even as management highlights growth in Imaging, Advanced Visualization Solutions and Pharmaceutical Diagnostics and completes the Intelerad acquisition. If GE HealthCare’s push into AI tools has caught your interest, it could be a good time to broaden your search and check out 40 healthcare AI stocks With GE HealthCare Technologies generating revenue of $20.98b and net income of $1.91b, yet the stock is down 13.44% over 1 year, investors are asking whether this weakness represents an opportunity or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 23% Undervalued Based on the most followed narrative, GE HealthCare Technologies is priced below an estimated fair value of $79.72 compared with the last close at $61.59, which puts a spotlight on the assumptions behind that gap.  The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.  Read the complete narrative. Read the complete narrative. Want to understand why this fair value sits well above today’s share price? The story leans heavily on steady growth in earnings, expanding margins and a future profit multiple that assumes investors stay comfortable with GE HealthCare’s long term role in imaging, diagnostics and AI driven tools. Result: Fair Value of $79.72 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, investors in GE HealthCare Technologies still need to weigh tariff exposure and China regulatory uncertainty, either of which could disrupt earnings expectations that underpin this undervalued narrative. Find out about the key risks to this GE HealthCare Technologies narrative. Next Steps Given this mix of concern and optimism around GE HealthCare Technologies, now is a good time to look through the numbers yourself and pressure test the assumptions. To see both sides of the story in one place, review the 4 key rewards and 1 important warning sign. Looking for more investment ideas beyond GE HealthCare Technologies? If GE HealthCare Technologies has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to uncover more stocks that could fit your approach.  Target steady compounding potential by focusing on companies with reliable cash flows and balance sheets using the solid balance sheet and fundamentals stocks screener (48 results). Hunt for potential mispriced opportunities by scanning companies that combine quality fundamentals with subdued valuations through the 45 high quality undervalued stocks. Put income first by searching for companies with higher yields and resilient payout profiles via the 8 dividend fortresses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645545044","isCrawlerRequest":true}